CO2023000068A2 - Anticuerpos anti-tgfβ y usos terapéuticos de estos - Google Patents

Anticuerpos anti-tgfβ y usos terapéuticos de estos

Info

Publication number
CO2023000068A2
CO2023000068A2 CONC2023/0000068A CO2023000068A CO2023000068A2 CO 2023000068 A2 CO2023000068 A2 CO 2023000068A2 CO 2023000068 A CO2023000068 A CO 2023000068A CO 2023000068 A2 CO2023000068 A2 CO 2023000068A2
Authority
CO
Colombia
Prior art keywords
tgfβ
antibodies
therapeutic uses
tgfβ antibodies
binding proteins
Prior art date
Application number
CONC2023/0000068A
Other languages
English (en)
Spanish (es)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Gary F Bammert
Sandra Ann Marie Lightle
Catherine J Strietzel
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CO2023000068A2 publication Critical patent/CO2023000068A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CONC2023/0000068A 2020-06-08 2023-01-05 Anticuerpos anti-tgfβ y usos terapéuticos de estos CO2023000068A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063036092P 2020-06-08 2020-06-08
PCT/US2021/036347 WO2021252455A1 (en) 2020-06-08 2021-06-08 ANTI-TGFβ ANTIBODIES AND THERAPEUTIC USES THEREOF

Publications (1)

Publication Number Publication Date
CO2023000068A2 true CO2023000068A2 (es) 2023-01-16

Family

ID=76708478

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0000068A CO2023000068A2 (es) 2020-06-08 2023-01-05 Anticuerpos anti-tgfβ y usos terapéuticos de estos

Country Status (13)

Country Link
US (1) US20220119513A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161654A1 (cg-RX-API-DMAC7.html)
JP (1) JP7798805B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230022974A (cg-RX-API-DMAC7.html)
CN (1) CN115803342A (cg-RX-API-DMAC7.html)
AU (1) AU2021287868A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024195A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186707A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000068A2 (cg-RX-API-DMAC7.html)
DK (1) DK202370008A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022015609A (cg-RX-API-DMAC7.html)
PH (1) PH12022500030A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021252455A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
CA3194936A1 (en) 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
CA3232382A1 (en) * 2021-09-27 2023-03-30 Zoetis Services Llc Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof
KR20250137204A (ko) 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
AU2023415535A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
CN117106082B (zh) * 2023-09-15 2024-10-29 成都蓉生药业有限责任公司 一种抗TGFβ的人源化纳米抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
MXPA01009363A (es) 1999-03-18 2002-06-04 Merck Patent Gmbh Proteina para bloquear la adhesion de plaquetas.
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1130098A3 (en) 2000-02-29 2003-09-10 Pfizer Products Inc. Mammalian osteoregulins
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2469833C (en) 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
CA2632799A1 (en) * 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
JP6495884B2 (ja) * 2013-03-11 2019-04-03 ジェンザイム・コーポレーション 改変抗tgfベータ抗体および抗原結合フラグメント
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β1的scFv-Fc二聚體
TW202506185A (zh) * 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
US20200392219A1 (en) * 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
EP3877055A1 (en) * 2018-11-05 2021-09-15 Ludwig Institute for Cancer Research Ltd Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof

Also Published As

Publication number Publication date
EP4161654A1 (en) 2023-04-12
DK202370008A1 (en) 2023-01-31
KR20230022974A (ko) 2023-02-16
JP2023530663A (ja) 2023-07-19
AU2021287868A1 (en) 2022-12-22
WO2021252455A1 (en) 2021-12-16
US20220119513A1 (en) 2022-04-21
MX2022015609A (es) 2023-04-20
PH12022500030A1 (en) 2024-02-26
JP7798805B2 (ja) 2026-01-14
BR112022024195A2 (pt) 2023-02-07
CA3186707A1 (en) 2021-12-16
CN115803342A (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
ZA202005189B (en) Anti-ngf antibodies and methods thereof
PH12022500030A1 (en) Anti-tgf㟠antibodies and therapeutic uses thereof
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
BR112012005970A2 (pt) moduladores tricíclicos de proteína quinase
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
HRP20250624T1 (hr) Sredstva, uporaba i metode za liječenje sinukleinopatije
BR112018072066A2 (pt) moléculas de ligação específicas para fcgamariia e uso das mesmas
AR120883A1 (es) Anticuerpos anti-fgfr2b
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
AR120886A1 (es) Anticuerpos anti-fgfr2b
MX2023004020A (es) Anticuerpos anti-ngf y métodos para su uso.
CO2024013551A2 (es) Nuevos anticuerpos anti-cd3 y usos de los mismos
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2021015501A (es) Anticuerpos y metodos de uso.
AR120884A1 (es) Anticuerpos anti-fgfr2b
CO2021014768A2 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
BR112022002236A2 (pt) Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
AR108790A1 (es) Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria
JOP20210009A1 (ar) طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
MX2024011886A (es) Anticuerpos contra siglec-9 humano y uso de estos para inmunoterapia